Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
Reshaping human antibodies for therapy
19881.2k citationsMike Clark, Herman Waldmann et al.profile →
Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo
1984804 citationsStephen Cobbold, Herman Waldmann et al.profile →
"Infectious" Transplantation Tolerance
1993722 citationsStephen Cobbold, Herman Waldmann et al.profile →
REMISSION INDUCTION IN NON-HODGKIN LYMPHOMA WITH RESHAPED HUMAN MONOCLONAL ANTIBODY CAMPATH-1H
1988550 citationsG Hale, Mike Clark et al.profile →
CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells.
1989547 citationsG Hale, Herman Waldmann et al.The Journal of Experimental Medicineprofile →
Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies.
1987501 citationsMike Clark, Herman Waldmann et al.The Journal of Experimental Medicineprofile →
Plasticity of Foxp3+ T Cells Reflects Promiscuous Foxp3 Expression in Conventional T Cells but Not Reprogramming of Regulatory T Cells
2012468 citationsHerman Waldmann, Shohei Hori et al.profile →
The plasticity and stability of regulatory T cells
Countries citing papers authored by Herman Waldmann
Since
Specialization
Citations
This map shows the geographic impact of Herman Waldmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Herman Waldmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Herman Waldmann more than expected).
This network shows the impact of papers produced by Herman Waldmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Herman Waldmann. The network helps show where Herman Waldmann may publish in the future.
Co-authorship network of co-authors of Herman Waldmann
This figure shows the co-authorship network connecting the top 25 collaborators of Herman Waldmann.
A scholar is included among the top collaborators of Herman Waldmann based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with Herman Waldmann. Herman Waldmann is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Waldmann, Herman. (2011). Plenary Session 3: Found in Translation: Learning Immunology from Human Therapeutic Trials. Immunology. 135. 24–24.1 indexed citations
Özkaynak, Engin, Ellen Triantafellow, Lisa M. Smith, et al.. (2005). Early infiltration of allografts by a subset of host mononuclear cells bearing inhibitory Ly49 receptors determines development of allograft rejection or tolerance.. American Journal of Transplantation. 5. 562–562.1 indexed citations
8.
Dick, Andrew D., K Greiner, J. Plšková, et al.. (2004). Neutralising TNF activity leads to remission in refractory posterior non-infectious uveitis. Bristol Research (University of Bristol). 1–1.1 indexed citations
9.
Peggs, K, Premini Mahendra, D W Milligan, et al.. (2003). Long term results of reduced intensity transplantation in multiply relapsed and refractory Hodgkin's lymphoma: Evidence of a therapeutically relevant graft-versus-lymphoma effect.. UCL Discovery (University College London).5 indexed citations
10.
Kottaridis, PD, DW Milligan, Charles Craddock, et al.. (2001). Non-myeloablative transplantation for patients with Hodgkin's disease: Limited transplant related mortality and possible evidence of a graft versus Hodgkin's effect.. UCL Discovery (University College London).4 indexed citations
11.
Lundin, Jeanette, Eva Kimby, Magnus Björkholm, et al.. (2001). Phase II study of subcutaneous alemtuzumab (Campath-1H) therapy of patients with previously untreated chronic lymphocytic leukemia (CLL).. Blood. 98.4 indexed citations
Treleaven, J, R Powles, S Kulkarni, et al.. (1996). Autografting with CD52 monoclonal antibody-purged marrow for acute lymphoblastic leukemia.. Blood. 88. 1009–1009.2 indexed citations
Adu, D., Caroline O.S. Savage, C M Lockwood, et al.. (1994). ANCA POSITIVE AND ANCA NEGATIVE MICROSCOPIC POLYARTERITIS. Journal of the American Society of Nephrology. 5(3). 825–825.4 indexed citations
16.
Isaacs, John D., et al.. (1994). AN IN-VIVO MODEL FOR DETERMINING RULES OF ANTIBODY DESIGN. Journal of Cellular Biochemistry. 206–206.1 indexed citations
17.
Naparstek, E, R. Or, Arnon Nagler, et al.. (1993). ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR LEUKEMIA USING CAMPATH-1 MONOCLONAL-ANTIBODIES AND POSTTRANSPLANT ALLOIMMUNIZATION WITH DONOR LYMPHOCYTES. Experimental Hematology. 21. 1061–1061.3 indexed citations
18.
Cullis, Jonathan, Richard Szydlo, Nicholas C.P. Cross, et al.. (1993). Matched unrelated donor bone marrow transplantation for chronic myeloid leukaemia in chronic phase: comparison of ex vivo and in vivo T-cell depletion.. PubMed. 11 Suppl 1. 107–11.8 indexed citations
19.
Clark, Mike & Herman Waldmann. (1989). THERAPY WITH HYBRID ANTIBODIES. British Journal of Cancer. 59(1). 304–304.3 indexed citations
20.
Waldmann, Herman, et al.. (1976). Antigen-non-specific T-cell factor in B-cell activation. Origin, biological properties and failure to show a relationship to H-2.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 30(5). 723–33.25 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.